retatrutide expanded access program FDA approves this year? Predictions & Odds 2026 Retatrutide approval: FDA status, clinical

Trends Cardiovasc

Others opt for evening or night-time injections, particularly if they experience mild gastrointestinal side effects, though this approach is based on anecdotal experience rather than clinical evidence, especially for once-weekly formulations

It might potentiate the appetite-blunting properties of estrogen and GLP-1, encouraging adherents to maintain new behaviors

Many insurance companies require physician documentation before approving treatment

GLP-1 injections are prescription weight loss treatments that contain synthetic versions of the GLP-1 hormone

Research Focus: It is being studied primarily for the treatment of obesity , type 2 diabetes , and fatty liver disease (MASH/MASLD).